Phase 2 data for atumelnant in adults with classic congenital adrenal hyperplasia (CAH) showed rapid, substantial and sustained reductions in androstenedione and 17-hydroxyprogesterone, with signals in clinical measures including decreased adrenal size and resumption of menses. Those biomarker and clinical effects set the context for Crinetics’ registrational move.
Crinetics has dosed the first patient in CALM-CAH, a randomized, placebo-controlled Phase 3 trial of atumelnant, a once-daily oral ACTH (MC2R) receptor antagonist, in adults with classic CAH. The study is designed to test whether the drug can normalize adrenal androgen levels while enabling reduction of exogenous glucocorticoids toward physiologic dosing, alongside other indicators of disease control. The program recently secured FDA Orphan Drug Designation, and the company is positioning the endpoint strategy to capture both biochemical control and steroid-sparing in a single registrational package.
Strategically, this is a direct, receptor-level counter to the leading development path in CAH, where several sponsors are pursuing CRF1 antagonists to lower ACTH upstream. By blocking MC2R, atumelnant aims to modulate adrenal steroidogenesis at the point of ACTH action, potentially offering more precise control over androgen excess and a clearer path to steroid reduction. The approach comes with different operational and safety considerations: overt antagonism at MC2R will force close monitoring for adrenal insufficiency and mineralocorticoid balance, but it could differentiate clinically if it delivers consistent androgen suppression without relying on broader hypothalamic–pituitary axis modulation. With a commercial endocrine franchise already on the market in acromegaly, Crinetics also brings active regulatory and launch infrastructure to a rare endocrine indication where execution speed and payer engagement matter.
For sites and CROs, CALM-CAH’s design points to a high-touch operational model: standardized steroid tapering algorithms, frequent centralized hormone assessments, and guardrails for adrenal crisis mitigation will be central to protocol fidelity. Expect reliance on specialty endocrine centers with adult CAH expertise, advocacy network referral pathways, and centralized labs for androstenedione and 17-OHP to manage variability. Imaging for adrenal volume and structured capture of menstrual and fertility metrics could add logistical load but may strengthen a multi-dimensional efficacy narrative. Vendors that can support rapid-turnaround assays and real-time safety monitoring will be advantaged, as will data platforms that can integrate taper decisions with blinded treatment assignments without undermining trial integrity.
What matters next is the fine print. Clarity on the primary endpoint structure, hierarchy, and the steroid-taper algorithm will determine regulatory readability and interpretability for payers. Safety will be scrutinized for adrenal insufficiency rates, electrolyte disturbances, and crisis events during taper. Magnitude and durability of androgen reduction, the proportion of patients reaching physiologic glucocorticoid dosing, and functional outcomes such as menses resumption and quality-of-life signals will shape competitiveness versus CRF1 antagonists moving through late-stage programs. Expansion into pediatric cohorts, read-through to ACTH-dependent Cushing’s, and the potential for an explicit steroid-sparing label claim are additional levers. The competitive risk is that cross-trial comparisons will favor whichever modality most cleanly balances biochemical control with fewer safety interventions. Watch for interim analyses, DSMB guidance on taper safety, and any alignment with FDA on registrational endpoints that could narrow time to filing if the Phase 3 signal tracks with Phase 2.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
